Glenn Hanna, MD

Medical Oncology

Glenn Hanna, MD

Dr. Hanna completed his fellowship training in hematology and medical oncology at Dana-Farber Cancer Institute in 2016. Prior to this, he earned his medical degree from Georgetown University School of Medicine in 2010, where he graduated summa cum laude, a member of Alpha Omega Alpha Honor Society and the Kober Medalist for academic excellence. He joined the faculty of the Center for Head and Neck Oncology in 2017. Dr. Hanna's clinical and translational research efforts are focused on both molecular and immunologic biomarker discovery to foster precision medicine approaches to treat head and neck cancers and improve patient outcomes. He maintains foundation and industry support to explore immuno-oncology approaches to treat head and neck cancers and high-risk oral precancerous lesions using novel combination immune checkpoint blockade, intra-tumoral injectables, and immune effector cell (IEC) therapies. He has additional interest in precision medicine approaches to treat salivary cancers of the head and neck, and in using cell-free DNA to treat and monitor human papillomavirus (HPV)-associated head and neck cancers.

View full profile

Related Videos

ASCO 2023: Head And Neck Research Presented by Glenn Hanna, MD Video

ASCO 2023: Head And Neck Research Presented by Glenn Hanna, MD

Encouraging anti-tumor activity for patients with metastatic head & neck squamous cell carcinoma who are HPV-negative and treated with bifunctional EGFR/TGF-beta inhibitor BCA101 w/pembrolizumab.

Glenn Hanna, MD Shares Phase 2 Study of Nivolumab for High-Risk Oral Leukoplakia Video

Glenn Hanna, MD Shares Phase 2 Study of Nivolumab for High-Risk Oral Leukoplakia

37% of patients with high-risk oral leukoplakia treated with preventative immunotherapy had proliferative leukoplakia regression and demonstrated favorable overall cancer-free survival.